Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Is serum TWEAK a useful biomarker of neuropsychiatric systemic lupus erythematosus

V. Balajkova, M. Olejarova, R. Moravcova, P. Kozelek, M. Posmurova, H. Hulejova, L. Senolt

. 2020 ; 69 (2) : 339-346. [pub] 20200323

Jazyk angličtina Země Česko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc21011354

The aim of this study was to determine the role of the tumor necrosis factor like weak inducer of apoptosis (TWEAK) as a serum biomarker of neuropsychiatric involvement in systemic lupus erythematosus (NPSLE). Levels of TWEAK levels were measured in sera of 92 patients with systemic lupus erythematosus (SLE), including 28 patients with neuropsychiatric lupus, and in 59 healthy controls using ELISA. All SLE patients underwent rheumatological, neurological and psychiatric assessment. We found no significant differences in TWEAK levels, between SLE patients and the healthy controls (p=0.2411). Similarly, no difference was observed between subgroup of NPSLE and healthy controls (p=0.7658). The mean SLE disease activity (SLEDAI) was 13.25. No correlations between TWEAK levels with disease activity (SLEDAI, r=0.2113, p=0.2805) or the most common NPSLE manifestations such as headache (r=0.2079), seizures (r=0.1101), cerebrovascular disease (r= 0.2347), cognitive dysfunction (r=0.1597) and anxiety (r=0.1397) were observed. Our data do not support the use of serum TWEAK as a discriminating biomarker for NPSLE. The role of the TWEAK in NPSLE remains to be investigated.

Citace poskytuje Crossref.org

Bibliografie atd.

Literatura

000      
00000naa a2200000 a 4500
001      
bmc21011354
003      
CZ-PrNML
005      
20210603093700.0
007      
ta
008      
210420s2020 xr d f 000 0|eng||
009      
AR
024    7_
$a 10.33549/physiolres.934308 $2 doi
035    __
$a (PubMed)32199014
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xr
100    1_
$a Balajková, Veronika $7 xx0232010 $u Department of Rheumatology, First Faculty of Medicine Charles University, Prague, Czech Republic
245    10
$a Is serum TWEAK a useful biomarker of neuropsychiatric systemic lupus erythematosus / $c V. Balajkova, M. Olejarova, R. Moravcova, P. Kozelek, M. Posmurova, H. Hulejova, L. Senolt
504    __
$a Literatura
520    9_
$a The aim of this study was to determine the role of the tumor necrosis factor like weak inducer of apoptosis (TWEAK) as a serum biomarker of neuropsychiatric involvement in systemic lupus erythematosus (NPSLE). Levels of TWEAK levels were measured in sera of 92 patients with systemic lupus erythematosus (SLE), including 28 patients with neuropsychiatric lupus, and in 59 healthy controls using ELISA. All SLE patients underwent rheumatological, neurological and psychiatric assessment. We found no significant differences in TWEAK levels, between SLE patients and the healthy controls (p=0.2411). Similarly, no difference was observed between subgroup of NPSLE and healthy controls (p=0.7658). The mean SLE disease activity (SLEDAI) was 13.25. No correlations between TWEAK levels with disease activity (SLEDAI, r=0.2113, p=0.2805) or the most common NPSLE manifestations such as headache (r=0.2079), seizures (r=0.1101), cerebrovascular disease (r= 0.2347), cognitive dysfunction (r=0.1597) and anxiety (r=0.1397) were observed. Our data do not support the use of serum TWEAK as a discriminating biomarker for NPSLE. The role of the TWEAK in NPSLE remains to be investigated.
650    _2
$a dospělí $7 D000328
650    _2
$a úzkost $x krev $x diagnóza $x psychologie $7 D001007
650    _2
$a biologické markery $x krev $7 D015415
650    _2
$a cytokin TWEAK $x krev $7 D000074049
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a vaskulitida centrálního nervového systému při lupus erythematodes $x krev $x diagnóza $x psychologie $7 D020945
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
655    _2
$a časopisecké články $7 D016428
700    1_
$a Olejárová, Marta $7 xx0060518 $u Department of Rheumatology, First Faculty of Medicine Charles University, Prague, Czech Republic
700    1_
$a Moravcová, Radka $7 xx0062182 $u Department of Rheumatology, First Faculty of Medicine Charles University, Prague, Czech Republic
700    1_
$a Kozelek, Petr $7 xx0143814 $u Psychiatric Clinic, First Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Pošmurová, Marie $7 xx0143812 $u Psychiatric Clinic, First Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Hulejová, Hana $7 xx0077461 $u Department of Rheumatology, First Faculty of Medicine Charles University, Prague, Czech Republic
700    1_
$a Šenolt, Ladislav, $d 1976- $7 xx0056558 $u Department of Rheumatology, First Faculty of Medicine Charles University, Prague, Czech Republic
773    0_
$w MED00003824 $t Physiological research $x 1802-9973 $g Roč. 69, č. 2 (2020), s. 339-346
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32199014 $y Pubmed
910    __
$a ABA008 $b A 4120 $c 266 $y p $z 0
990    __
$a 20210420 $b ABA008
991    __
$a 20210519151316 $b ABA008
999    __
$a ok $b bmc $g 1659424 $s 1131733
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 69 $c 2 $d 339-346 $e 20200323 $i 1802-9973 $m Physiological research $n Physiol. Res. (Print) $x MED00003824
LZP    __
$b NLK118 $a Pubmed-20210420

Najít záznam

Citační ukazatele

Možnosti archivace